GLP-1 medicines and research materials
“GLP-1” and “research peptide” describe different things
GLP-1 identifies glucagon-like peptide-1 and its associated receptor terminology. “Research peptide” describes a material's laboratory supply context. These are not mutually exclusive chemical categories: a peptide associated with GLP-1 receptor research is still a peptide. Neither label establishes the identity, specification or authorised use of a particular vial.
For a meaningful comparison, ask four questions separately: which molecule is named, which targets are studied, what evidence exists for that molecule, and what preparation is actually supplied. A broad category label cannot answer all four.
One receptor family does not mean one compound
The receptor descriptions used for Semaglutide, Tirzepatide and Retatrutide are different. The three-compound comparison sets out their identities and evidence boundaries. Describing a compound as dual- or triple-targeted is not a ranking of product quality or a claim that one can replace another.
Retatrutide's development identifier is LY3437943. The original discovery report by Coskun and colleagues describes activity at GLP-1, GIP and glucagon receptors using defined experimental systems. The phase 1b report by Urva and colleagues concerns a clinical-development preparation and a specified study population. Neither publication analyses a PCUK batch.
Read the evidence at its actual level
| Evidence | Question it may address |
|---|---|
| Chemical identity record | Which structure the name denotes |
| Receptor or cell assay | Behaviour in that experimental system |
| Animal study | Findings in the studied species and conditions |
| Human study | Findings in its participants with its study preparation |
| Batch analytical report | Identity, composition or purity of the tested sample by stated methods |
Moving from one row to another requires additional evidence. A chromatogram does not establish a clinical outcome. A clinical paper does not establish the identity of a commercial vial. Even a shared compound name does not demonstrate equivalent formulation, manufacturing controls or analytical specification.
Laboratory listings and finished medicines
A listed laboratory reagent is not a finished medicine. Product authorisation, where it exists, belongs to the particular medicine and its approved conditions. A research-use label does not transfer that authorisation to another preparation. PCUK's supplied materials remain restricted to non-clinical in-vitro laboratory research.
What to compare on a product page
For Retatrutide 10mg, 20mg and 30mg, compare the labelled quantities, current availability and batch-document links. Quantity is a supplied format, not an administration instruction. Use the Retatrutide identity reference for nomenclature and the COA guide to interpret the product's documentary evidence.
EPS documentation
Use the research catalogue to check the exact name, labelled amount and format. The COA library publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.